HealthcareServices

Vasoactive Intestinal Peptide Tumor Industry Poised for Rapid Growth, Forecast to Touch $2.14 Billion by 2030 at 6% CAGR

March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the vasoactive intestinal peptide tumor market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Vasoactive Intestinal Peptide Tumor Market in 2030?

The vasoactive intestinal peptide tumor market size has demonstrated robust growth in recent years. This market is projected to expand from $1.61 billion in 2025 to $1.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.2%. The expansion witnessed in the historic period is attributable to improved detection of neuroendocrine tumors, increased availability of specialized oncology centers, the growing application of imaging-based diagnostics, the early adoption of somatostatin analog therapies, and advancements in pancreatic surgery techniques.

The market size for vasoactive intestinal peptide tumors is anticipated to experience substantial growth over the upcoming years, expanding to $2.15 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.0%. This projected expansion during the forecast period can be attributed to several factors, including rising research investments dedicated to rare cancers, the increasing development of novel targeted drugs, a growing adoption of precision medicine approaches, the expansion of specialized cancer care infrastructure, and increasing awareness of rare endocrine disorders. Furthermore, major trends expected in the forecast period involve the increasing adoption of targeted therapy approaches, a rising use of advanced imaging techniques for early diagnosis, a growing focus on personalized treatment protocols, the expansion of minimally invasive surgical techniques, and an enhanced integration of multidisciplinary care models.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23561&type=smp

What Drivers Are Influencing Production Trends In The Vasoactive Intestinal Peptide Tumor Market?

The vasoactive intestinal peptide tumor market is anticipated to expand due to the increasing prevalence of targeted therapy. These therapies are designed to concentrate on particular molecules or pathways critical to disease progression, especially in cancer, allowing them to precisely eliminate abnormal cells while sparing healthy ones. The expansion of targeted therapies is largely influenced by precision medicine, which boosts effectiveness by addressing specific genetic mutations and simultaneously reducing adverse effects. In the context of VIP tumors, targeted treatments function by inhibiting vital pathways that contribute to tumor growth and hormone secretion. This action aids in decreasing VIP levels, thereby alleviating symptoms like severe diarrhea and decelerating the disease’s advancement. For example, the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, reported in July 2024 that 76 gene therapy trials were initiated in the second quarter of 2024, representing a 25 % increase from the preceding quarter. Hence, the increasing application of targeted therapy is a key factor propelling the growth of the vasoactive intestinal peptide tumor market.

Which Segment Groups Are Influencing The Vasoactive Intestinal Peptide Tumor Market?

The vasoactive intestinal peptide tumor market covered in this report is segmented –

1) By Treatment: Surgical Intervention, Radiotherapy, Chemotherapy, Targeted Therapy

2) By Diagnosis: Imaging Techniques, Biopsy, Endoscopic Ultrasound

3) By Therapeutic Approach: Palliative Care, Curative Treatment, Adjuvant Treatment

4) By End-User: Hospitals, Cancer Specialty Clinics, Diagnostic Laboratories

Subsegments:

1) By Surgical Intervention: Tumor Resection, Debulking Surgery, Minimally Invasive Surgery

2) By Radiotherapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy

3) By Chemotherapy: Cytotoxic Chemotherapy, Combination Chemotherapy, Adjuvant And Neoadjuvant Chemotherapy

4) By Targeted Therapy: Somatostatin Analog Therapy, Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies

What Upcoming Trends Are Likely To Define The Future Path Of The Vasoactive Intestinal Peptide Tumor Market?

Major companies engaged in the vasoactive intestinal peptide tumor market are directing their attention towards developing advanced offerings, such as long-acting injectable suspensions, to improve treatment effectiveness, enhance patient adherence, and ensure sustained symptom relief. Long-acting injectable suspensions are pharmaceutical formulations designed to gradually release their active ingredients over an extended timeframe, thereby reducing the need for frequent dosing. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., a US-based pharmaceutical company, launched the first and only generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the U.S. This medication is utilized for long-term maintenance therapy in acromegaly patients who did not adequately respond to surgery or radiotherapy. It also addresses severe diarrhea and flushing associated with metastatic carcinoid tumors and VIP-secreting tumors. The introduction highlights Teva’s expertise in complex generic products and supports its aim of maintaining a strong presence in the generic pharmaceuticals market.

Who Are The Primary Competitors In The Global Vasoactive Intestinal Peptide Tumor Market?

Major companies operating in the vasoactive intestinal peptide tumor market are Pfizer Inc., Novartis AG, Mayo Clinic, Mount Sinai Hospital, Cleveland Clinic Laboratories, Penn Medicine, Stanford Health Care, UCSF Health, ARUP Laboratories, Dr. Lal PathLabs, Cancer Research UK, Medicover Hospitals, Ganesh Diagnostic, Ipsen Pharma SA, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Merck & Co

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/vasoactive-intestinal-peptide-tumor-global-market-report

Which Regions Are Projected To Dominate The Vasoactive Intestinal Peptide Tumor Market In The Coming Years?

North America was the largest region in the vasoactive intestinal peptide tumor market in 2025. The regions covered in the vasoactive intestinal peptide tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Vasoactive Intestinal Peptide Tumor Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23561&type=smp

Browse Through More Reports Similar to the Global Vasoactive Intestinal Peptide Tumor Market 2026, By The Business Research Company

Gastrointestinal Stromal Tumor Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-stromal-tumor-global-market-report

Glucagon Like Peptide 1 Market Report 2026

https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795